drugset / Trial / NCT00114361

48 Weeks Combination Therapy for Patients With HBeAg-negative Chronic Hepatitis B Virus (HBV) Infection

NCT00114361

Phase 3 Completed 138 enrolled Foundation for Liver Research
RandomizedFactorialDouble-blind

Summary

The purpose of this study is to investigate whether in patients with chronic HBeAg-negative hepatitis B, PEG-IFN-ribavirin combination therapy for 1 year leads to enhanced response (HBV DNA \<10E4 copies/ml and normal ALT 24 weeks after treatment discontinuation) in comparison with pegylated interferon (PEG-IFN) monotherapy.

Timeline

Start
2005-03
Primary completion
2008-05
Completion
2010-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Peginterferon alfa-2a Protein / enzyme biologic 180 ug
Comparator Ribavirin Small molecule 1200 mg